The global dilated cardiomyopathy market is anticipated to grow significantly over the forecast period. Dilated cardiomyopathy (DCM) is a cardiac disorder caused by enlargement of heart. The muscular walls of the heart become weak due to enlargement and hence heart is not able to pump blood efficiently. The disorder affects liver, lungs, and other important organs of the body steadily. It is the clinical condition that causes enlargement of initially left vertical of the heart, which is considered as the main pumping chamber. Significantly, it may spread to the right chamber over time. DCM also leads to frequent blood clots, irregular heartbeats, and valve problems, which may affect any person irrespective of age and sex, although the probability ratio of males over females is 3:1.
Various treatments available for DCM focuses on the improvement of blood flow which is its underlying cause. The treatment of the DCM can be done with two techniques one is by oral drug and the other is implantable devices. The types of DCM drugs available are beta-blockers, diuretics, digitalis, angiotensin 2 receptor blocker, warfarin, diuretics, and angiotensin-converting enzyme inhibitors. In the second category of treatment, implantable devices, heart pumps, and cardioverter-defibrillators are prominently used.
The main causes of DCM are infections in cardiac muscles, genetics or birth defects, drug or alcohol abuse, or certain exposure to toxic substances such as mercury, lead or cobalt. In some of the cases, DCM may also be caused as a side effect of cancer medication.
DCM is most common in 20 to 60 years of children. The major symptoms of DCM are frequent shortness of breath and fatigue and swelling on lower extremities, the sudden gaining of weight, sudden fainting, dizziness, blood clots, and chest pain.
An increase in life expectancy of individuals and a prominent increase in the number of heart problems over the years are prominent for the development of the dilated cardiomyopathy market. Whereas, increase in health awareness among the people is one of the biggest restraints for the growth of the market.
The geographical market segment of the dilated cardiomyopathy market is divided into four parts namely North America, Europe, Asia-Pacific, and RoW. Asia-Pacific and North America are expected to be growth leaders of the DCM market due to an increase in the number of heart diseases over the years. Europe with high medical infrastructure has a large market but growth prospects are less. RoW is expected to remain another prominent market.
The main market players involved in the treatment of DCM with the manufacturing of drugs or devices are ZensunSci& tech, Capricor Therapeutics, Aastrom Biosciences, t2cure GmbH, MyoKardia, and Kasiak Research pvt.ltd.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.